These findings suggest that the fusion to anti-CD20 antibodies of the mutein IL-2no-alpha that expands preferentially CD8+ T lymphocytes and NK cells over Tregs with less toxicity than IL-2 (25), may be a good effective therapeutic against human lymphomas. The gene discussed is CD8A; the disease is lymphoma.